Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Biotecnología

Mr. Nigel J. Baade B.Com, Grad. Dip., CPA

Chief Financial Officer & Company Sec.

Mr. Nigel J. Baade B.Com, CPA, Grad. Dip.

Chief Financial Officer

Ms. Tracy  Weimar BA, MBA

Interim Company Sec.

Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), GAICD, MBA

Chief Executive Officer, MD & Executive Director

Mr. Justin  Cahill

Joint Company Sec.

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M
Immuron Limited	0M
Aptevo Therapeutics Inc.	0M

Starpharma Holdings Limited

Starpharma Holdings Limited Lista de competidores

Principales competidores